Journal of Clinical OncologySystemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation

The Sartor, et al randomized controlled trial (RCT), which demonstrated a significant improvement in radiographic progression-free survival and overall survival (OS) in patients with PSMA-positive mCRPC, served as the foundation for the ¹⁷⁷Lutetium-PSMA-617 (¹⁷⁷Lu-PSMA-617) March 2022 approval. The availability of this theranostic option served as a compelling argument for revising the 2014 proposal to include a prompt endorsement of ¹⁷⁷Lu-PSMA-617. The mCRPC recommendations are now being updated completely.